STOCKHOLM – Medivir AB (NASDAQ Stockholm: MVIR), a biopharmaceutical firm specializing in most cancers drug improvement, introduced as we speak a rise in its variety of shares and votes following current share points. The corporate accomplished a rights difficulty on November 7, 2023, and a directed share difficulty to Hallberg Administration AB on January 22, 2024. These transactions resulted in a complete improve of 56,211,817 unusual shares.
As of the final buying and selling day of January, Medivir has a complete of 112,917,968 shares, comprising 112,053,218 unusual shares and 864,750 class C-shares. The overall variety of votes quantities to 112,139,693, with every unusual share entitled to at least one vote and every class C-share entitled to one-tenth of a vote.
Medivir’s operations are centered on the event of revolutionary medication for most cancers remedy, particularly in areas with excessive unmet medical wants. The corporate’s present focus is on fostroxacitabine bralpamide (fostrox), a pro-drug geared toward treating liver most cancers with minimal unintended effects. Collaborations and partnerships are a major facet of Medivir’s enterprise technique, with drug improvement being pursued independently or along side companions.
The corporate’s share is listed on the Nasdaq Stockholm Small Cap record. This info, required to be disclosed below the Swedish Monetary Devices Buying and selling Act, was launched for publication on the time acknowledged by the corporate’s information distributor.
The announcement of the share and vote improve relies on a press launch assertion from Medivir.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.